Canopy shares plunge as pot producer posts another loss


A sign featuring Canopy Growth Corporation’s logo is pictured at their facility in Smiths Falls, Ontario, Canada, January 4, 2018. REUTERS/Chris Wattie/File Photo/File Photo

Register now for FREE unlimited access to

Aug 5 (Reuters) – Canopy Growth Corp (WEED.TO), posted another core loss on Friday, denting investor hopes that the cannabis producer would turn profitable anytime soon, sending its shares down 8%.

The company’s quarterly gross margin was impacted by a decline in production, lower prices in the Canadian recreational business, a shift in business mix and a fall in government payroll subsidies related to a COVID-19 relief program.

Canopy has been focusing on premium high-potency offerings and has undertaken cost cuts through layoffs, exits from some international markets and store closures in its bid to turn profitable, after nearly four years of cannabis legalization in Canada.

Register now for FREE unlimited access to

Some of these cost-saving measures are being offset by higher wage inflation and supply-chain costs, Chief Financial Officer Judy Hong said in a call, adding that the majority of the savings are expected to be recognized in the second half of fiscal 2023.

“We expect cost savings to ramp in the second half of the year,” Hong added. Canopy achieved more than C$40 million ($30.96 million) of savings in the quarter.

Canopy earlier this year extended its time frame to achieve profitability as fewer-than-expected retail stores and cheaper black market rates crimp sales at legal recreational companies.

The company, which had first aimed to turn profitable by the second half of 2022, now expects to report core earnings only in fiscal 2024, excluding certain investments. Analysts estimate it will be delayed by another year.

The cannabis producer also took a hit of C$1.73 billion in the quarter due to asset impairment charges and restructuring costs, forcing it to post a net loss from year-ago profit.

It posted an adjusted core loss of C$74.8 million in the first quarter ended June 30, compared with a loss of C$63.6 million a year earlier.

($1 = 1.2919 Canadian dollars)

Register now for FREE unlimited access to

Reporting by Rithika Krishna and Arunima Kumar in Bengaluru; Editing by Vinay Dwivedi

Our Standards: The Thomson Reuters Trust Principles.

Read More

Affiliate disclosure: The links contained in this product review may result in a small commission if you opt to purchase the product recommended at no additional cost to you. This goes towards supporting our research and editorial team and please know we only recommend high quality products.

Disclaimer: Please understand that any advice or guidelines revealed here are not even remotely a substitute for sound medical advice from a licensed healthcare provider. Make sure to consult with a professional physician before making any purchasing decision if you use medications or have concerns following the review details shared above. Individual results may vary as the statements made regarding these products have not been evaluated by the Food and Drug Administration. The efficacy of these products has not been confirmed by FDA-approved research. These products are not intended to diagnose, treat, cure or prevent any disease.


Please enter your comment!
Please enter your name here